188
Participants
Start Date
March 25, 2016
Primary Completion Date
December 4, 2019
Study Completion Date
December 4, 2019
MEDI3902
Participants will receive a single IV dose of MEDI3902 500 mg and 1500 mg in MEDI3902 500 mg arm and MEDI3902 1500 mg arm, respectively.
Placebo
Participants will receive a single IV dose of placebo matched to MEDI3902.
Research Site, Dublin
Research Site, Brussels
Research Site, Vienna
Research Site, Brussels
Research Site, Budapest
Research Site, Ottignies
Research Site, Vác
Research Site, Genk
Research Site, Innsbruck
Research Site, Ankara
Research Site, Haine-Saint-Paul
Research Site, Bruges
Research Site, Ghent
Research Site, Athens
Research Site, Athens
Research Site, Athens
Research Site, Córdoba
Research Site, Athens
Research Site, Athens
Research Site, Annapolis
Research Site, Madrid
Research Site, San Sebastián de los Reyes
Research Site, Getafe
Research Site, Atlanta
Research Site, Augusta
Research Site, Gainesville
Research Site, Oviedo
Research Site, Montpellier
Research Site, Istanbul
Research Site, Slavonski Brod
Research Site, Tours
Research Site, La Tronche
Research Site, Santander
Research Site, Larissa
Research Site, Larissa
Research Site, Tarragona
Research Site, Cincinnati
Research Site, Valencia
Research Site, Valladolid
Research Site, Detroit
Research Site, Nancy
Research Site, Thessaloniki
Research Site, Lille
Research Site, Trabzon
Research Site, Clermont-Ferrand
Research Site, Strasbourg
Research Site, Pierre-Bénite
Research Site, Paris
Research Site, Paris
Research Site, Paris
Research Site, Paris
Research Site, Englewood
Research Site, Limoges
Research Site, Jerusalem
Research Site, Le Plessis-Robinson
Research Site, Garches
Research Site, Le Kremlin-Bicêtre
Research Site, Argenteuil
Research Site, Petah Tikva
Research Site, Ramat Gan
Research Site, Tel Aviv
Research Site, Boston
Research Site, Brno
Research Site, Děčín
Research Site, Kolín
Research Site, Kyjov
Research Site, Teplice
Research Site, Kistarcsa
Research Site, Almada
Research Site, Lisbon
Research Site, Lisbon
Research Site, Viana do Castelo
Research Site, Barcelona
Research Site, Barcelona
Research Site, Terrassa
Research Site, Edgbaston
Research Site, London
Research Site, London
Lead Sponsor
Innovative Medicines Initiative
OTHER
Antibacterial Resistance Leadership Group
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
MedImmune LLC
INDUSTRY